Absorption, distribution, metabolism and excretion of daily oral doses of [14C]methyl parathion in hens

被引:21
|
作者
Abu-Qare, AW [1 ]
Abdel-Rahman, AA [1 ]
Ahmad, H [1 ]
Kishk, AM [1 ]
Abou-Donia, MB [1 ]
机构
[1] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA
关键词
methyl parathion; p-nitrophenol; pharmacokinetics; hens; organophosphates;
D O I
10.1016/S0378-4274(01)00409-X
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Adult hens were given oral daily doses of 2 mg (2 muC(i))/kg/day (14% of oral LD50 in male rats) of [C-14]methyl parathion (O,O-dimethyl O-4-nitrophenyl phosphorothioate) for 10 consecutive days. Five treated hens were sacrificed at 1, 2, 4, 8, 12, 24, and 48 h after the last dose. Methyl parathion was absorbed from the gastrointestinal tract and distributed rapidly. Maximum radioactivity was detected in tissues within 8 h of dosing, (ng methyl parathion equivalent/g fresh tissue or ml plasma): Plasma (189.2), liver (94.7), kidney (146.2), brain (61.4), gastrointestinal tissues (106.7). Methyl parathion was detected in the plasma, kidney and liver, while methyl parathion metabolite p-nitrophenol was detected in the liver and in the kidney. Elimination of methyl parathion from plasma was monophasic with a terminal half-life of 17.5 h, corresponding to an elimination rate constant of 0.039 ng/hr. Most of the absorbed radioactivity was excreted in the combined fecal-urine excreta (98%). Analysis of the metabolites in the excreta revealed that non-conjugated metabolites accounted for 13% of the total excretion. Conjugated metabolites accounted for 87% of the total excretion; of that, 6% as p-nitrophenyl-glucoronide conjugate, 7% as p-nitrophenyl-sulfate conjugate, 23% as bound hot sulfric acid hydrolyzable residues, and 51% as water soluble metabolites. The presence of majority of radioactivity in the excreta as conjugated metabolites indicates that determining only unbound p-nitrophenol as a biological marker for methyl parathion exposure underestimates total fecal-urine excretion of p-nitrophenol. The slow elimination rate of methyl parathion is significant, since hens are more comparable to humans with respect to their cytochrome P450 activities. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 50 条
  • [41] Evaluation of the distribution and excretion of [14C]-inclisiran following single subcutaneous administration in cynomolgus monkeys
    Lehoux, Dario
    Far, Adel Rafai
    Kallend, David
    Wijngaard, Peter L. J.
    Zerler, Brad
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2022, 443
  • [42] Pharmacokinetics, metabolism, and excretion of [14C]-valemetostat in healthy male participants, and in vitro plasma protein binding
    Masaya Tachibana
    Nicholas Siebers
    Thuy Vu Craveiro
    Miho Kazui
    Tomoko Ikeda
    Takako Shimizu
    Shinichi Inaba
    Malaz A. Abutarif
    Cancer Chemotherapy and Pharmacology, 2025, 95 (1)
  • [43] A phase I study to investigate the metabolism, excretion, and pharmacokinetics of [14C]fruquintinib, a novel oral selective VEGFR inhibitor, in healthy Chinese male volunteers
    Zhou, Sufeng
    Shao, Feng
    Xu, Zhaoqiang
    Wang, Lu
    Jin, Ke
    Xie, Lijun
    Chen, Juan
    Liu, Yun
    Zhang, Hongwen
    Ou, Ning
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (03) : 563 - 573
  • [44] A phase I study to investigate the metabolism, excretion, and pharmacokinetics of [14C]fruquintinib, a novel oral selective VEGFR inhibitor, in healthy Chinese male volunteers
    Sufeng Zhou
    Feng Shao
    Zhaoqiang Xu
    Lu Wang
    Ke Jin
    Lijun Xie
    Juan Chen
    Yun Liu
    Hongwen Zhang
    Ning Ou
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 563 - 573
  • [45] Bioavailability, Metabolism, and Excretion of [14C]-Tazemetostat in Patients With B-Cell Lymphomas or Advanced Solid Tumors
    Chen, Yingxue
    Teng, Renli
    Ogier, Julien
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2025, : 231 - 239
  • [46] Metabolism, pharmacokinetics and excretion of the GABAA receptor partial agonist [14C]CP-409,092 in rats
    Kamel, A.
    Obach, R. S.
    Tseng, E.
    Sawant, A.
    XENOBIOTICA, 2010, 40 (06) : 400 - 414
  • [47] Investigation of in vitro absorption, distribution, metabolism, and excretion and in vivo pharmacokinetics of paromomycin: Influence on oral bioavailability
    Jakir, M.
    Pinjari, S. K.
    Somani, Rahul
    Gilhotra, Ritu M.
    INDIAN JOURNAL OF PHARMACOLOGY, 2017, 49 (04) : 297 - 303
  • [48] In Vivo Absorption, Distribution, Excretion, and Metabolism of a New Herbicide, Methiozolin, in Rats following Oral Administration
    Hwang, Ki-Hwan
    Lim, Jong-Soo
    Kim, Sung-Hun
    Jeon, Man-Seok
    Lee, Dong-Guk
    Chung, Kun-Hoe
    Koo, Suk-Jin
    Kim, Jeong-Han
    JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2013, 61 (39) : 9285 - 9292
  • [49] Metabolism and Excretion of [14C] Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase, in Healthy Male Subjects
    Grabowski, Brian A.
    Khosravan, Reza
    Vernillet, Laurent
    Mulford, Darcy J.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (02) : 189 - 201
  • [50] Absorption and disposition including enterohepatic circulation of (14C) roquinimex after oral administration to healthy volunteers
    Strandgården, K
    Höglund, P
    Grönquist, L
    Svensson, L
    Gunnarsson, PO
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2000, 21 (02) : 53 - 67